Case report
Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast

Veronica Ann Varney*, Helen Parnell, Chandrarshekar Malapanjudi Jagadish, Ziyad Abubacker
Respiratory Dept, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, SM5 1AA, United Kingdom

ARTICLE INFO
Keywords:
Cough
Roflumilast
Tracheobronchomalacia
Immunology of roflumilast

ABSTRACT
This case report describes a patient with moderately severe tracheobronchomalacia following mycoplasma pneumonia. The patient was considered to have obstructive lung disease despite no prior smoking or lung disease and failure to respond to standard treatment. The possibility of tracheal pathology causing cough and sputum was not considered in 23yrs confirming this to be a “forgotten zone”. The patient was treated with Roflumilast to reduce airway secretions with great success and the Immunology of Roflumilast is discussed.

1. Case history

A 73yr old man was referred for a further opinion on his 23 year problem of persistent cough with difficulty expectorating. The onset appeared to follow a mycoplasma pneumonia associated with a peri-carditis, prior to which he had no respiratory diseases at all. He had never smoked and previous CT scans of his chest and sinuses were report normal without evidence of sinus disease, bronchiectasis or chronic obstructive pulmonary disease to account for his persistent cough and sputum. When expectorated his sputum was opalescent mucoid material and yellow or green during infections. In the 23yrs of this affliction the working diagnosis had mainly been COPD as past spirometry was always reduced: PEFR 70% predicted, FEV1 81% predicted, FVC 68% predicted.

He had worked in the building trade and his BMI was 34. Treatment for COPD and asthma in the form of long acting anti-muscarinics and long acting beta-2 agonists with inhaled steroids gave no benefit and he felt made things worse. Assessment of the immune system excluded immunodeficiency and allergy. Regular physiotherapy, an acapello de and chest pains from incessant efforts to clear sputum. Cardiac investigations were normal. Enalapril for hypertension had been discontinued without benefit to his cough many years before. There was no history of choking on food or drink and nothing to suggest aspiration or micro-aspiration, and his voice was normal.

His past medical history included hypertension, type-2 diabetes mellitus, a hiatus hernia and diverticular disease. Medication consisted of bisoprolol 2.5mg, Ezetimibe 10mg, felodipine 2.5mg, Irbesartan 300mg, liraglitide 1.2mg daily subcutaneously, metformin 1.5 gms/day, Vitamin D3 1000units/day, co-codamol 8hrly as required. Azithromycin 250mg on Monday and Friday had given benefit to the cough and reduced sputum volume for up to 18 months following which he relapsed back to his prior state despite continuing that treatment. As every avenue had now failed to benefit him, he was left to manage as best he could. In November 2018, due to his poor life quality from his chronic cough, he was referred for further opinion. He gave a very clear account of all that had gone before. On auscultation he had audible loose sputum rattling over his large airways that did not clear with coughing and without associated wheeze. Expectorating the material was difficult and made no discernible difference to the cough, as any successful clearance still left more sputum waiting to be cleared. Spirometry then showed Fev1 2.2L (predicted 81%), FVC 2.6 (74%), PEFR 350 (predicted 72%).

Bronchoscopy (his first) was performed which showed normal nares, no sinus discharge but glue-like secretions clinging to the laryngeal wall with acid burns to the vocal cords. The cords were normal and adducted fully, indicating that cough should be effective. The trachea was tortuous with a reduction in the tracheal lumen longitudinally upon

Abbreviations: COPD, chronic obstructive airways disease; FEV1, forced expiratory volume in 1 second; PEFR, peak expiratory flow rate; TM, Tracheomalacia; TBM, tracheobronchomalacia; EDAC, excessive dynamic airway collapse; CT, computerised tomography; EGFR, Epithelial growth factor receptor.

* Corresponding author.
E-mail address: veronica.varney@nhs.net (V.A. Varney).

https://doi.org/10.1016/j.rmcr.2020.101247
Received 8 February 2020; Received in revised form 17 September 2020; Accepted 7 October 2020
Available online 22 October 2020
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
coughing from bulging-in of the posterior membrane of the trachea (excessive dynamic airway collapse). The carina was significantly reduced to <5mm in its AP diameter on expiration suggesting tracheobronchomalacia, and closed completely upon coughing trapping secretions below the carina. There were copious glue-like secretions in both main bronchi undoubtedly from failure to be expectorated into the trachea but the distal airways were otherwise normal. These secretions were irritating the airway and triggering the cough receptors. Bacterial and TB cultures from bronchial washings were negative but the secretions showed a neutrophil infiltrate.

A niopam swallow test was normal without aspiration onto the trachea. No hiatus hernia was present but occasional tertiary contractions were noted.

In view of the known immunological effects of roflumilast on bronchial secretions, a trial of this drug at the regular dose of 500mcg/day was commenced. After 1 month there was a possible reduction in cough. As sputum in the airway reduced, his need to cough reduced with an improved quality of life and better sleep.

Symptoms have improved by the month since commencing roflumilast. A dynamic CT scan of the trachea and carina confirmed expiratory airway collapse that was more marked on the left (see Fig. 1) and consistent with tracheobronchomalacia. This condition can be treated with airway stenting; but stents themselves can move and may cause infection and coughing. This is the first report of roflumilast treatment used to reduce airway secretions and cough in tracheobronchomalacia.

His sleep is now prolonged without disturbance by cough and daytime coughing is greatly reduced giving a significant improvement in life quality (score 8 out of 10 for improvement) relative to what had gone before. Spirometry in December 2019; Fev1 2.1 (predicted 77%) FVC 2.62 (predicted 72%), PEFR 340 (predicted 75%). There have been no exacerbations, emergency hospital attendances nor steroid or antibiotic required in the 18 months on treatment.

2. Tracheobronchomalacia

The trachea has the potential to be the forgotten zone and doesn’t receive much prominence or clinical consideration in the differential diagnosis of chronic cough with sputum [1].

The upper airway includes all the structures from the nasopharynx down to the carina. The trachea is beyond visualisation except by Bronchoscopy or CT scan. It can be affected by infectious or systemic inflammatory diseases, trauma, congenital abnormalities and even malignancy. External compression by adjacent structures can also occur [2] (See Table 1). Patients with tracheal abnormalities are frequently misdiagnosed as having obstructive lung disease but do not respond to bronchodilators which can worsen the condition by relaxing smooth muscle.

[3]. The normal trachea is slightly oval in shape with an AP diameter that is greater than its transverse diameter and resists deformation during a normal and a forced respiratory cycle (Fig. 1).

Tracheomalacia (TM) causes dynamic collapse of the trachea in expiration. This occurs through loss of tracheal rigidity or loss of cartilage integrity with susceptibility to collapse that can be localised or diffuse [4]. This can produce symptoms of chronic cough with sputum and occasionally haemoptysis. TM may impair clearance of secretions and give increased risk of respiratory infection. Most cases are simply considered to have respiratory infections due to a lack of clinical awareness of this condition. Occasionally it is an incidental finding during other investigations with its significance not fully recognised. In TM, the AP diameter of the trachea is reduced to give a crescent shape deformity also known as a scabbard shape.

If only the lateral walls of the trachea narrow, this is called a sabrethatch type deformity which is rarer but associated with COPD resulting from mechanical forces of hyperinflation and hyper compliance distorting the intrathoracic trachea.

Clinically relevant TM requires >70% narrowing of the trachea in expiration relative to inspiration to confirm the diagnosis. Some cases may therefore be missed if narrowing is in the 50–70% range. TM is considered mild if the trachea AP-diameter is reduced to <50% in expiration, moderate if reduced by >70% and severe if the walls touch. Tracheobronchomalacia (TBM) is the term used to describe the condition when the main stem bronchi are also involved in expiratory collapse as well as the trachea as in this patient’s case [2,5].

Experiments show the FEV-1 still remains >90% of predicted until the tracheal orifice is reduced to 6mm. Spirometry is therefore not a sensitive measure of TM or TBM. In such cases reduced spirometry is attributed to asthma or COPD. Peak flow abnormalities are more sensitive. Flow/volume loops can be abnormal (a saw-toothed pattern in the expiratory flow) and give clues to airway collapse but only when the upper airway narrows to <8mm, so they do not preclude an upper airway disorder from the differential diagnosis. When there is dyspnoea at rest the trachea is reduced to 5mm!

Excessive dynamic airway collapse (EDAC) occurs due to weakness

![Fig. 1. Show tracheal narrowing in expiration (A) and trachea in inspiration (B) with dynamic CT views taken just above the carina.](image)

| Table 1 Causes of tracheomalacia. |
|----------------------------------|
| Infections | Viral (H1N1, adenovirus, corona virus), bacterial, fungal (aspergillosis). |
| **Inflammatory/infiltrative** | Sarcoidosis, amyloidosis, rheumatoid, Wegener’s granulomatosis, mustard gas, necrotising tracheitis, polyangitis |
| **Non-inflammatory** | Trauma, idiopathic tracheal stenosis, Mounier-Kuhn syndrome, Relapsing polychondritis. |
| **Iatrogenic** | Post tracheal intubation, high dose prednisolone |
| **Neoplastic** | Primary or secondary |
| **Extrinsic compression** | Lymph node enlargement, vascular anomalies, fibrosing mediastinitis, mediastinal granuloma, goitre |
and bowing of the posterior tracheal membrane into the trachea giving an inverted U-shaped airway with >50% reductions in sagittal diameter during expiration. Unlike TM or TBM, EDAC is not related to structural or functional cartilaginous pathology but may coexist [1,6].

Examination of the trachea should be considered in patients with atypical features or those in whom treatment failure occurs or appears to run a difficult clinical course. To make a diagnosis at Bronchoscopy, narrowing of the tracheal AP diameter should be >70% when directly viewed under tidal breathing and also forced expiratory manoeuvres. This is a gold standard method for evaluating airway collapse.

Dynamic expiratory CT imaging of the trachea has emerged as a non-invasive alternative to Bronchoscopy and can be very useful for large airway pathology. Dynamic CT in TM shows comparable accuracy to Bronchoscopy with greater end expiratory sensitivity [7].

Acquired TM in adults is commonest in men >40yrs and recognised causes are listed in Table 1.

### 2.1. Immunology of roflumilast

Roflumilast is a selective phosphodiesterase-4 inhibitor now licensed for severe Chronic Obstructive Pulmonary Disease (COPD) with frequent exacerbations. There is particular benefit for those with a significant daily component of chronic bronchitis [8]. Roflumilast gives increased levels of intracellular cyclic AMP which produces a wide range of anti-inflammatory effects. This includes reduced inflammatory mediators and cell surface markers with reduced apoptosis. It is clear from animal studies that roflumilast affects different parts of the immune system changing mediator release relevant to airway remodelling in both COPD and chronic asthma through its effects on cellular cyclic AMP [9].

Roflumilast selectively reduces pro-inflammatory cytokines and growth factors believed to be involved in the pathogenesis of airway disease in asthma (Table 2). In murine models of chronic asthma, roflumilast reduces airway inflammation and hyper-responsiveness with reduced goblet cell hyperplasia and fibrosis, that are involved in airway remodelling and the proliferation of fibroblasts [10].

In COPD, roflumilast significantly reduces sputum neutrophilia and eosinophilia by 35% and 50% respectively relative to placebo treatment. These reductions in sputum cell counts are proportional to the cells already in the sputum and include monocytes and lymphocytes. As a result, the release of neutrophil and eosinophil inflammatory signals are reduced (Table 2). There is a reduction in the sputum concentrations of alpha-2 macroglobulin indicating reduced micro-vascular leak which may be the mechanism of the reduced sputum cell counts [9]. In COPD, spirometry improves with roflumilast treatment relative to placebo along with significantly reduced exacerbations [8].

### Table 2

| Mediator | Action of mediator | Effect of roflumilast | reference |
|----------|-------------------|----------------------|-----------|
| Interleukin-6 (IL-6) | Activates monocytes, fibroblasts and B cell. | ↓ | 15-17 |
| Interleukin-8 (IL-8) | Enhances neutrophil chemotaxis | ↓ | 15-17 |
| Tumour Necrosis factor-α (TNF-α) | From leukocytes and activates inflammatory cells + increases e-selection on vascular endothelium | ↓↓ | 15 |
| E-Selectin | Increases movement of leukocytes into endothelium | ↓ | 15 |
| Transforming growth factor β1 (TGF-β1) | Cell growth + proliferation + apoptosis | ↓ | 9 |
| Eosinophil cationic protein | Cytotoxic + promotes fibrosis | ↓ | 19 |
| Neutrophil elastase | Stimulates mucus secretion + degrades connective tissue | ↓↓ | 19 |
| Fibroblast growth factor | Regulates cell proliferation + wound repair | ↓ | 15 |

In the respiratory tract, mucus is a critical component of innate host defence; in the bronchial airways this is produced by goblet cells and sub-mucous glands. Mucus hyper-secretion is a hallmark of chronic airways disease with animal models identifying activation of epithelial growth factor receptor (EGFR) as central to this. EGFR expression is increased by TNF-α (tumour necrosis factor-α) and positively correlates with the level of goblet cell hyperplasia. Both neutrophils and monocytes can generate TNF-α along with reactive oxygen series and both can activate EGFR. It is likely that the reduction in airway neutrophils and also the ability of roflumilast to reduce TNF-α has reduced mucus production in this patient probably via effects upon EGFR expression [11, 12].

Roflumilast is well tolerated with a bioavailability of 80%. The parent drug is 3-times more potent than its metabolite. Metabolism is hepatic via the cytochrome P450 system (phase 1) followed by conjugation (Phase 2). Hepatic dysfunction may impair elimination but a dose adjustment is not required, although severe hepatic dysfunction is a contraindication to use [13].

The co-prescription of drugs that are strong cyp3A4 or dual cyp 3A4 + cyp 1A2 inhibitors such as erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine, and rifampicin should be avoided. Azithromycin has only weak effects on cyp3A4 without producing adverse effects if taken with roflumilast. Patients taking glucagon-like peptide-1 (incretin) to stimulate insulin release from the pancreas in diabetes may have increased drug levels with improved glycaemic control. The manufacturers suggest avoiding concomitant theophylline.

Side effects from roflumilast include nausea, diarrhoea and weight loss, insomnia and reduced appetite. They should be avoided in patients with prior immune suppression in case of detrimental effects [14].

### 3. Conclusion

The ability of roflumilast to reduce airway secretions in chronic bronchitis along with its other known immunological properties as a selective phosphodiesterase-4 inhibitor was the reason why it was considered for this patient. Benefit to the patient has been life transforming without any significant side effects, improving with treatment duration and no exacerbations have occurred on treatment. Lung function shows a small improvement, but the main benefit is through reduced airway secretions with reduced cough. Roflumilast may have benefits in other respiratory diseases though its immunological effects including of course asthma and possibly hypersensitivity pneumonitis and even Sarcoidosis.

This case report describes a patient with moderately severe tracheobronchomalacia following mycoplasma pneumonia. The patient was considered to have obstructive lung disease despite no previous smoking or lung disease and clear failure to respond to standard treatment. The possibility of tracheal pathology causing cough and sputum was not considered in 23yrs confirming this to be a forgotten zone.

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.
2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving...
any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions

Entity: government agency, foundation, commercial sponsor, academic institution, etc. Grant: A grant from an entity, generally [but not always] paid to your organization Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance,

Administrative support etc

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent.

1. Given Name (First Name)Veronica
2. Surname (Last Name) Varney
3. Are you the corresponding author? Yes No
4. Date8/2/20
5. Manuscript TitleLongstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to Roflumilast
6. Manuscript Identifying Number (if you know it)

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? Yes No

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.

Declaration of competing interest

The authors have no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rmcr.2020.101247.

References

[1] K. Malvi, A. Padmanabhan, T.A. Han, An undiagnosed cause of chronic cough, J. Fam. Med. Prim. Care 4 (4) (2015) 598–600.
[2] M.O. Al-Qadi, A.W. Artenstein, S.S. Braman, The forgotten zone: acquired disorders of the trachea in adults, Respir. Med. 107 (2013) 1301–1313.
[3] S.B. Hobbs, C.M. Walker, B.W. Carter, J.H. Chung, Progressive dyspnoea in a patient with a patient in a patient with asthma: insights on computed tomographic imaging of the airway, Ann Am Thorac Soc 13 (2) (2016) 292–294.
[4] K.A. Garden, P.M. Boiselle, D.A. Waltz, Ernst A. Tracheomalacia and tracheomalacia in adults: an in-depth review, Chest 127 (2005) 984–1005.
[5] C. Kagler, F. Stanzel, Tracheomalacia. Thorac Surg Clin 24 (2014) 51–58.
[6] S. Murgu, H. Colt, Tracheomalacia and excessive dynamic airway collapse, Clin. Chest Med. 34 (2013) 527–555.
[7] J.H. Chung, J.P. Kanee, M.D. Gilman, CT of diffuse tracheal diseases, Am. J. Roentgenol. 196 (2011) 240–246.
[8] J.A. Wedzicha, P.M.A. Calverley, K.F. Rabe, Roflumilast: a review of its use in the treatment of COPD, Int J of COPD 11 (2016) 81–90.
[9] D.C. Grocottsdor, S.A. Gauw, R.M. Verhoosel, P.J. Sterk, J.J. Hosper, D. Bredenbrocker, T.D. Bethke, P.S. Huisma, K.F. Rabe, Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD, Thorax 62 (2007) 1081–1087.
[10] S.W. Kim, J.H. Kim, C.K. Park, T.J. Kim, S.Y. Lee, S.S. Kwon, C.K. Rhee, H.K. Yoon, Effects of roflumilast on airway remodelling in a murine model of chronic asthma, Clin. Exp. Allergy 46 (5) (2016) 754–763.
[11] E.V.S. Ha, D.F. Rogers, Novel therapies that inhibit mucus synthesis and secretion in airway hyper-secretory disease, Pharmacology 97 (2016) 84–100.
[12] L. Cohn, Mucus in chronic airway diseases; sorting out the sticky details, J. Clin. Invest. 116 (2) (2006) 306–308.
[13] R. Hermann, N. Nasser, G. Lahu, Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis, Clin. Pharmacokin. 46 (5) (2007) 403–416.
[14] P.M.A. Calverley, L.M. Fabbri, K.F. Rabe, H. Mosberg, Roflumilast in the treatment of COPD: A pooled safety analysis, Eur. Respir. J. 36 (54) (2010) P4401.
[15] Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Kumar RK. Suppression of Cytokine expression by Roflumilast and Dexamethasone in a Model of Chronic Asthma. Clinical & Experimental allergy DOI.org/10.1111/J.1365-2222.2008.02950.X.
[16] V.M. Keatings, P.D. Collins, D.M. Scott, Differences in interleukin -8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease of asthma, Am. J. Respir. Crit. Care Med. 153 (1996) 530–534.
[17] A. Hatzelmann, C. Schudt, Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro, J. Pharmacol. Exp. Therapeut. 297 (2001) 280–290.

[18] G.C. Ruse, S. Larsson, G.C. Lofdahl, Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis, Eur. Respir. J. 7 (1994) 1673–1677.

[19] K. Fujimoto, K. Kubo, H. Yamamoto, Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema, Chest 115 (1999) 697–703.